Navigation Links
Telik Announces Top-Line Results From Assist-5 Trial of Telcyta(R) in Combination With Pegylated Liposomal Doxorubicin in Platinum Refractory and Resistant Ovarian Cancer
Date:10/29/2008

biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA(R), a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA, a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP(R), which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at http://www.telik.com.

This press release contains "forward-looking" statements. These include statements concerning the potential for TELCYTA to treat ovarian cancer and the effectiveness of TELCYTA in combination with PLD and in patients under certain platinum refractory and platinum resistant conditions. These forward-looking statements are based upon Telik's current expectations. There are important factors that could cause Telik's results to differ materially from those indicated by these forward-looking statements, including the risks associated with clinical trials and the interpretation of resulting data. Detailed information regarding these and other factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in Telik's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its quarterly report on Form 10-Q for the quarter ended June 30, 2008. Telik does not undertake any obligation to update forward-looking statements contained in this press release.

TELIK, the Telik logo, TELINTRA, TELCYTA, and TRAP are trademarks or registered trademarks of Telik, Inc. '/>"/>

SOURCE Telik, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Telik Announces 2008 Third Quarter Financial Release, Conference Call and Webcast
2. Telik Announces Receipt of Nasdaq Notice
3. Teliks Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone
4. ReceptorBio Announces Diabetes License Agreement With Telik
5. Telik Announces Financial Results For 2008 Second Quarter
6. Telik Announces 2008 Second Quarter Financial Release, Conference Call and Webcast
7. Telik Announces Publication of Diabetes Research in Bioorganic & Medicinal Chemistry Letters
8. Telik Announces Presentation and Webcast at Needham Biotechnology Conference
9. Telik Announces First Quarter 2008 Financial Results
10. Telik Presents Preclinical Data at 99th Annual Meeting of the American Association for Cancer Research
11. Telik Announces Fourth Quarter and 2007 Year End Financial Results and 2008 Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... Quebec , November 21, 2014 ... wechselt als Chief Commercial Officer zu KLOX ... SVP der Unternehmensentwicklung und Chief Financial Officer bestellt    ... Europa mit der Vermarktung seines jüngst zugelassenen Behandlungssystems zur ... Inc. ("KLOX" bzw. das "Unternehmen") ist sehr erfreut, die ...
(Date:11/21/2014)... Author Matthew J. Pallamary’s second short story ... published as a tribute to his mentor Ray ... Story” category of the 2014 USA Best Book ... USA Book News, said this year’s contest yielded over ... & Schuster, Penguin, John Wiley & Sons, Houghton Mifflin ...
(Date:11/21/2014)... Angeles, CA (PRWEB) November 21, 2014 ... it that makes Albert Einstein so instantly recognizable? Why ... African-born physicist, mathematician, astronomer and author Hilton Ratcliffe seeks ... they have nothing at all to do with science. ... Muse Harbor Publishing , November 21, 2014), Ratcliffe puts ...
(Date:11/21/2014)... SAN DIEGO , Nov. 20, 2014  Cytori ... CEO Marc Hedrick , M.D. will present live at ... December 4, 2014 TIME:    11:15 am PT / ... paste this URL into your browser,s address bar: http://bit.ly/1B2KGaL ... save time and receive event updates. This ...
Breaking Biology Technology:KLOX Technologies meldet Neubesetzung von Führungspositionen 2KLOX Technologies meldet Neubesetzung von Führungspositionen 3KLOX Technologies meldet Neubesetzung von Führungspositionen 4KLOX Technologies meldet Neubesetzung von Führungspositionen 5Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 2Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 3Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 4“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 2“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 3“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 4Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 2Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 3Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 4
... Merrimack Pharmaceuticals today announced that it will present at the Jefferies 2010 Global Life Sciences Conference ... provide a company overview at 11:00am EDT , Wednesday, June 9, 2010 at ... , , ... , , , ...
... June 1 Diplomat Specialty Pharmacy, the ... launch of Navigator Health Services, an independent division of ... pharmacy industry. The announcement was made by Diplomat Specialty ... who says that Navigator Health Services was formed in ...
... Calif. , June 1 Epeius Biotechnologies Corporation ( ... "Advanced Phase I/II Evaluation of Tumor-Targeted Gene Delivery: Intravenous Rexin-G as ... the ASCO Annual Meeting on June 8, 2010 . The ... Stanford University Medical Center, Palo Alto CA. ...
Cached Biology Technology:Merrimack Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference 2Diplomat Specialty Pharmacy Launches New Navigator Health Services to Meet Next Generation Needs of Specialty Pharmacy Industry 2Diplomat Specialty Pharmacy Launches New Navigator Health Services to Meet Next Generation Needs of Specialty Pharmacy Industry 3Diplomat Specialty Pharmacy Launches New Navigator Health Services to Meet Next Generation Needs of Specialty Pharmacy Industry 4Advanced Phase I and Phase II Studies of Targeted Gene Delivery Confirm That Rexin-G Impacts Survival in Chemotherapy-resistant Bone and Soft Tissue Sarcoma (ASCO 2010) 2
(Date:11/11/2014)... 11, 2014  Forensicon, Inc., a Chicago ... to announce the promotion of Yaniv Schiff ... Forensics. In Schiff,s new role as Director, he will ... digital forensics examiners and provide leadership within the company,s ... http://photos.prnewswire.com/prnh/20141110/157719 Schiff joined Forensicon ...
(Date:11/7/2014)... Calif. , Nov. 7, 2014  In conjunction with ... Police Departments, The Community Foundation of the Verdugos ... DNA JUSTICE PROJECT," a $250,000 initiative to keep ... initial phase. In its first six months of existence, the ... needed evidence support for local law enforcement. "Because ...
(Date:11/6/2014)... of metastasis, yet progress in preventing and treating ... been particularly challenging to design drugs that work ... systems biology at Harvard Medical School. , ... already metastasized." , Gujral and colleagues have now ... better understand how metastasis begins. Their findings may ...
Breaking Biology News(10 mins):Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2Migration negation 2Migration negation 3
... New results presented at 3rd European Lung Cancer Conference ... improve the diagnosis and treatment of malignant pleural mesothelioma, ... lungs caused by asbestos exposure. Micro RNAs ... small molecule that is more abundant in the blood ...
... Ecological Society of America,s (ESA) 97th Annual Meeting on August ... draw more than 4,300 scientists, policy makers, educators and concerned ... State marine ecologist and head of the National Oceanic and ... keynote address on Sunday, August 5th, at 5:00 p.m. ...
... (April. 17, 2012) Combined, complimentary therapies have the ... (NSC) transplantation for spinal cord repair in rat models, ... of Korean researchers who published in a recent issue ... http://www.ingentaconnect.com/content/cog/ct/ ., "When transplanted, neural stem cells ...
Cached Biology News:Promising developments in early diagnosis and treatment of mesothelioma 2Promising developments in early diagnosis and treatment of mesothelioma 3Promising developments in early diagnosis and treatment of mesothelioma 4Registration open for the Ecological Society of America's 2012 Annual Meeting in Portland, Ore. 2Neural stem cell transplants for spinal cord injury maximized by combined, complimentary therapies 2
... 1 ml. Improves reproducibility and ... preventing streaking.Eliminates extra spots caused ... proteins throughout entire 2-D runs, ... patterns.Ideal for both analytical and ...
LIVE/DEAD® Cell-Mediated Cytotoxicity Kit *for animal cells* *2000 assays*...
SlowFade Antifade Kit with DAPI...
Mouse Collagen IV...
Biology Products: